Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Roché H, et al. Among authors: delozier t. J Clin Oncol. 2006 Dec 20;24(36):5664-71. doi: 10.1200/JCO.2006.07.3916. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116941 Clinical Trial.
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
Fumoleau P, Chauvin F, Namer M, Bugat R, Tubiana-Hulin M, Guastalla JP, Delozier T, Kerbrat P, Devaux Y, Bonneterre J, Filleul A, Clavel M. Fumoleau P, et al. Among authors: delozier t. J Clin Oncol. 2001 Feb 1;19(3):612-20. doi: 10.1200/JCO.2001.19.3.612. J Clin Oncol. 2001. PMID: 11157010 Clinical Trial.
Pirarubicin in advanced breast cancer: a French cooperative phase II study.
Spielmann M, Kerbrat P, Delozier T, Fumoleau P, Monnier A, Chevallier B, Bastit P, Namer M, Cattan A, Lucas P, et al. Spielmann M, et al. Among authors: delozier t. Eur J Cancer. 1990;26(7):821-3. doi: 10.1016/0277-5379(90)90161-l. Eur J Cancer. 1990. PMID: 2145903
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, et al. Garcia-Giralt E, et al. Among authors: delozier t. Breast Cancer Res Treat. 1992;24(2):139-45. doi: 10.1007/BF01961246. Breast Cancer Res Treat. 1992. PMID: 8443401 Clinical Trial.
Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
Delozier T, Spielmann M, Macé-Lesec'h J, Janvier M, Hill C, Asselain B, Julien JP, Weber B, Mauriac L, Petit JC, Kerbrat P, Malhaire JP, Vennin P, Leduc B, Namer M. Delozier T, et al. J Clin Oncol. 2000 Oct 15;18(20):3507-12. doi: 10.1200/JCO.2000.18.20.3507. J Clin Oncol. 2000. PMID: 11032592 Clinical Trial.
89 results